On October 28, 2026, HHS and the FDA opened an interim path for licensed 503A pharmacies to compound six peptides (BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax) by prescription. Here is what changed, what it means for patients, and why sourcing from a quality compounding pharmacy matters more than ever.

A pharmacist's guide to compounded eflornithine cream for unwanted facial hair — how it slows growth, the results to realistically expect, side effects, cost, and how it compares to Vaniqa.

Emideltide—better known as delta sleep-inducing peptide or DSIP—was the only one of seven peptides not recommended by PCAC in July 2026. Here is what the evidence and vote mean.

Semax is a synthetic ACTH-derived heptapeptide studied primarily in Russian neurological research. It is not FDA approved. Here is what is known about its proposed uses and PCAC’s 2026 recommendation.

Epitalon—also spelled Epithalon—is promoted as a sleep and longevity peptide. Laboratory and animal findings are intriguing, but claims of proven human anti-aging effects are not supported by robust trials.

MOTS-c is a mitochondrial-derived peptide studied for metabolic signaling, exercise adaptation and aging. Most intervention data remain preclinical. Here is the science and current FDA status.

TB-500 is often marketed as thymosin beta-4, but FDA evaluated a specific seven-amino-acid fragment. Learn what research exists, where claims outrun evidence, and what PCAC’s favorable vote means.